BioGenCell has joint forces with Newcastle University Institute of Cellular Medicine, Institute for Cell and Molecular Bioscience and North East England Stem Cell Institute and with the Laniado diabetes center in Israel for research on a new regenerative medicine. All parties have embarked on a collaborative venture, bringing together different cell therapies that are currently pioneered in both countries towards a simple and persuasive new combination therapeutic of donor-derived pancreatic islets and patient’s own endothelial progenitor cells.

Comments are closed.